Shifting the disease management paradigm from glucose: what are the pros?

Diabetes Care. 2009 Nov;32 Suppl 2(Suppl 2):S349-52. doi: 10.2337/dc09-S337.

Authors

Alin Stirban¹, Diethelm Tschoepe, Bernd Stratmann

Affiliation

¹ Diabetes Center, Heart and Diabetes Center NRW Bad Oeynhausen, Ruhr-University Bochum, Bochum, Germany.

No abstract available

Publication types

Review

MeSH terms

Atherosclerosis / epidemiology
Blood Pressure
Diabetes Mellitus, Type 2 / blood
Diabetes Mellitus, Type 2 / epidemiology*
Diabetes Mellitus, Type 2 / prevention & control
Diabetic Angiopathies / epidemiology
Diabetic Neuropathies / epidemiology
Diabetic Retinopathy / epidemiology
Glycated Hemoglobin / metabolism
Glycation End Products, Advanced / metabolism
Humans
Lipids / blood
Obesity / epidemiology
Obesity / prevention & control
Platelet Count
Prevalence
Risk Factors

Substances

Glycated Hemoglobin A
Glycation End Products, Advanced
Lipids